Durham, N.C.-based Dova Pharmaceuticals Inc., a small rare disease company gearing up for the potential launch of a pre-registration drug for treating thrombocytopenia, has priced an underwritten public offering expected to raise as much as $80.9 million. Funds from the offering, in which shares will be sold at $32 each, would support a potential June launch of avatrombopag in the U.S. for patients with chronic liver disease, and work to expand the drug's approved uses to the treatment of a broader population of patients with thrombocytopenia.